
Topic
Generics
ANDA strategy, Paragraph IV risk, therapeutic equivalence, supply concentration, and price erosion.

Generics· June 27, 2026 · 18 min read
By Ran Chen#Generics#FDA Approval#Ophthalmology

Generics· June 26, 2026 · 22 min read
Generic Revlimid REMS Launch: Lenalidomide ANDA Entry and NADAC Absence
By Ran Chen#Generics#Orange Book#Oncology

Generics· June 26, 2026 · 21 min read
Generic Tecfidera: Dimethyl Fumarate Patent Settlements and NADAC Erosion
By Ran Chen#Generics#Orange Book#PBM

Generics· June 26, 2026 · 21 min read
Generic Zytiga: Abiraterone Acetate ANDA Saturation and NADAC Pricing
By Ran Chen#Generics#Orange Book#Oncology

Generics· June 25, 2026 · 19 min read
Generic Copaxone: FDA Guidance and NADAC Pricing Dynamics
By Ran Chen#Generics#Orange Book#FDA Approval

Generics· June 25, 2026 · 19 min read
Generic Forteo: Drug-Device Pathways and PBM Exclusions
By Ran Chen#Generics#Orange Book#505(b)(2)

Generics· June 25, 2026 · 19 min read
Generic Gilenya: Dosing Patent Expiry and 99% Price Erosion
By Ran Chen#Generics#Orange Book#PBM

Generics· June 24, 2026 · 17 min read
Generic Entresto Market Entry: 95% Price Erosion and the Payer Formulary Transition
By Ran Chen#Generics#Generic Entry#Drug Pricing

Pricing & Access· June 24, 2026 · 25 min read
Novartis Portfolio Dossier: Spinoff Splits and Patent Cliffs
By Ran Chen#Orange Book#Purple Book#Generics

Pricing & Access· June 24, 2026 · 26 min read
Pfizer Portfolio Dossier: Patent Cliffs, Shortages, and Recalls
By Ran Chen#Orange Book#Purple Book#FDA Approval